Brosnan Cashman J, Yuan M, Graham M, Rizzo A, Myers K, Davis C, et al. ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. PLoS ONE. 2018;13:e0204159 pubmed publisher

Valle García D, Qadeer Z, McHugh D, Ghiraldini F, Chowdhury A, Hasson D, et al. ATRX binds to atypical chromatin domains at the 3' exons of zinc finger genes to preserve H3K9me3 enrichment. Epigenetics. 2016;11:398-414 pubmed publisher

Enomoto T, Aoki M, Hamasaki M, Abe H, Nonaka M, Inoue T, et al. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis. Neurol Med Chir (Tokyo). 2020;60:136-146 pubmed publisher

Han M, Napier C, Frölich S, Teber E, Wong T, Noble J, et al. Synthetic lethality of cytolytic HSV-1 in cancer cells with ATRX and PML deficiency. J Cell Sci. 2019;132: pubmed publisher

Diplas B, He X, Brosnan Cashman J, Liu H, Chen L, Wang Z, et al. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Nat Commun. 2018;9:2087 pubmed publisher

Deeg K, Chung I, Bauer C, Rippe K. Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition. Front Oncol. 2016;6:186 pubmed publisher

Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto Korander R, et al. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12. PLoS Genet. 2016;12:e1005850 pubmed publisher

Neumann J, Spohn M, Obrecht D, Mynarek M, Thomas C, Hasselblatt M, et al. Molecular characterization of histopathological ependymoma variants. Acta Neuropathol. 2020;139:305-318 pubmed publisher

Kwon M, Kang S, Cho H, Lee J, Kim S, Suh Y. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. Brain Pathol. 2020;30:235-245 pubmed publisher

Liang J, Liu H, Li G, Qian J, Gao R, Zhou Y, et al. Global changes in chromatin accessibility and transcription following ATRX inactivation in human cancer cells. FEBS Lett. 2020;594:67-78 pubmed publisher

Wang L, Li Z, Piao Y, Cai Y, Zhang L, Ge H, et al. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas. Chin Med J (Engl). 2019;132:2920-2926 pubmed publisher

Qadeer Z, Valle García D, Hasson D, Sun Z, Cook A, Nguyen C, et al. ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures. Cancer Cell. 2019;36:512-527.e9 pubmed publisher

Liang J, Zhao H, Diplas B, Liu S, Liu J, Wang D, et al. Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition. Cancer Res. 2019;: pubmed publisher

Kim G, Rincon Fernandez Pacheco D, Saxon D, Yang A, Sabet S, Dutra Clarke M, et al. Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements. Cell. 2019;179:251-267.e24 pubmed publisher

Rodriguez F, Graham M, Brosnan Cashman J, Barber J, Davis C, Vizcaíno M, et al. Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathol Commun. 2019;7:139 pubmed publisher

Burford C, Laxton R, Sidhu Z, Aizpurua M, King A, Bodi I, et al. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas. Br J Neurosurg. 2019;33:536-540 pubmed publisher

Steele C, Tarabichi M, Oukrif D, Webster A, Ye H, Fittall M, et al. Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell. 2019;35:441-456.e8 pubmed publisher

Yost K, Clatterbuck Soper S, Walker R, Pineda M, Zhu Y, Ester C, et al. Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells. Sci Rep. 2019;9:4544 pubmed publisher

D Angelo F, Ceccarelli M, Tala -, Garofano L, Zhang J, Frattini V, et al. The molecular landscape of glioma in patients with Neurofibromatosis 1. Nat Med. 2019;25:176-187 pubmed publisher

Morshed R, Han S, Hervey Jumper S, Pekmezci M, Troncon I, Chang S, et al. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60. J Neurooncol. 2019;141:383-391 pubmed publisher

Vizcaíno M, Palsgrove D, Yuan M, Giannini C, Cabrera Aldana E, Pallavajjala A, et al. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma. Brain Pathol. 2019;29:193-204 pubmed publisher

Rodriguez F, Brosnan Cashman J, Allen S, Vizcaíno M, Giannini C, Camelo Piragua S, et al. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. Brain Pathol. 2019;29:126-140 pubmed publisher

Bell W, Meeker A, Rizzo A, Rajpara S, Rosenthal I, Flores Bellver M, et al. A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease. Brain Pathol. 2019;29:45-52 pubmed publisher

Kafka A, Karin Kujundžić V, Serman L, Bukovac A, Njirić N, Jakovcevic A, et al. Hypermethylation of Secreted Frizzled Related Protein 1 gene promoter in different astrocytoma grades. Croat Med J. 2018;59:213-223 pubmed

Chou A, Itchins M, de Reuver P, Arena J, Clarkson A, Sheen A, et al. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Hum Pathol. 2018;82:249-257 pubmed publisher

Bieńkowski M, Wöhrer A, Moser P, Kitzwögerer M, Ricken G, Strobel T, et al. Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach. Clin Neuropathol. 2018;37:166-177 pubmed publisher

Tauziède Espariat A, Saffroy R, Pages M, Pallud J, Legrand L, Besnard A, et al. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations. Clin Neuropathol. 2018;37:209-216 pubmed publisher

Lu H, Eulo V, Apicelli A, Pekmezci M, Tao Y, Luo J, et al. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. Oncotarget. 2018;9:23018-23028 pubmed publisher

Li N, Zhang Y, Sidlauskas K, Ellis M, Evans I, Frankel P, et al. Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades. Oncogene. 2018;37:4313-4333 pubmed publisher

Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, et al. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. Biomed Res Int. 2018;2018:7945845 pubmed publisher

Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, et al. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocr Relat Cancer. 2018;25:619-631 pubmed publisher

Ballester L, Boghani Z, Baskin D, Britz G, OLSEN R, Fuller G, et al. Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins. Brain Pathol. 2018;28:1012-1019 pubmed publisher

Kim S, Lee Y, Won J, Park C, Choi S, Park S. Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. J Pathol Transl Med. 2018;52:28-36 pubmed publisher

Panse G, Chrisinger J, Leung C, Ingram D, Khan S, Wani K, et al. Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. Histopathology. 2018;72:239-247 pubmed publisher

Fereidouni F, Harmany Z, Tian M, Todd A, Kintner J, McPherson J, et al. Microscopy with ultraviolet surface excitation for rapid slide-free histology. Nat Biomed Eng. 2017;1:957-966 pubmed

Li X, Wei J, Liu Y, Li P, Fan L, Wang Y, et al. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. Sci Rep. 2017;7:13038 pubmed publisher

Bielle F, Di Stefano A, Meyronet D, Picca A, Villa C, Bernier M, et al. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features. Brain Pathol. 2017;: pubmed publisher

Lee Y, Koh J, Kim S, Won J, Park C, Choi S, et al. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. Acta Neuropathol Commun. 2017;5:62 pubmed publisher

Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, et al. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. J Neuropathol Exp Neurol. 2017;76:697-708 pubmed publisher

Uekawa K, Nakamura H, Shinojima N, Takezaki T, Yano S, Kuratsu J. Adult Diffuse Astrocytoma in the Medulla Oblongata: Molecular Biological Analyses Including H3F3A Mutation of Histone H3.3. NMC Case Rep J. 2016;3:29-33 pubmed publisher

Park J, Paik W, Lee K, Ryu J, Lee S, Kim Y. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget. 2017;8:49796-49806 pubmed publisher

Cleven A, Suijker J, Agrogiannis G, Briaire de Bruijn I, Frizzell N, Hoekstra A, et al. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clin Sarcoma Res. 2017;7:8 pubmed publisher

Kiviniemi A, Gardberg M, Kivinen K, Posti J, Vuorinen V, Sipila J, et al. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Oncotarget. 2017;8:49123-49132 pubmed publisher

Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, et al. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. Oncotarget. 2017;8:41044-41063 pubmed publisher

Vandenbussche C, Allison D, Graham M, Charu V, Lennon A, Wolfgang C, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2017;125:544-551 pubmed publisher

Pekmezci M, Rice T, Molinaro A, Walsh K, Decker P, Hansen H, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133:1001-1016 pubmed publisher

Kim J, Brosnan Cashman J, An S, Kim S, Song K, Kim M, et al. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017;23:1598-1606 pubmed publisher

Li Y, Shi Z, Aibaidula A, Chen H, Tang Q, Li K, et al. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. Oncotarget. 2016;7:64615-64630 pubmed publisher

Slatter T, Hsia H, Samaranayaka A, Sykes P, Clow W, Devenish C, et al. Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. J Pathol Clin Res. 2015;1:95-105 pubmed publisher

Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira R, Gonçalves A, et al. TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Sci Rep. 2016;6:29714 pubmed publisher

Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A, et al. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2017;23:600-609 pubmed publisher

Oktay Y, Ãœlgen E, Can Ã, Akyerli C, Yüksel Å, Erdemgil Y, et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Sci Rep. 2016;6:27569 pubmed publisher

Solomon D, Wood M, Tihan T, Bollen A, Gupta N, Phillips J, et al. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations. Brain Pathol. 2016;26:569-80 pubmed publisher

Oh J, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, et al. Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma. Brain Pathol. 2016;26:517-22 pubmed publisher

Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, et al. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. Br J Cancer. 2015;113:1244-8 pubmed publisher

Koelsche C, Renner M, Johann P, Leiss I, Sahm F, Schimmack S, et al. Differential nuclear ATRX expression in sarcomas. Histopathology. 2016;68:738-45 pubmed publisher

Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, et al. ATRX represses alternative lengthening of telomeres. Oncotarget. 2015;6:16543-58 pubmed

Hayashi S, Sasaki H, Kimura T, Abe T, Nakamura T, Kitamura Y, et al. Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort. Oncotarget. 2015;6:15871-81 pubmed

Reis G, Pekmezci M, Hansen H, Rice T, Marshall R, Molinaro A, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol. 2015;74:442-52 pubmed publisher

Fishbein L, Khare S, Wubbenhorst B, Desloover D, D Andrea K, Merrill S, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140 pubmed publisher

Howitt B, Sholl L, Dal Cin P, Jia Y, Yuan L, MacConaill L, et al. Targeted genomic analysis of Müllerian adenosarcoma. J Pathol. 2015;235:37-49 pubmed publisher